140710-90-3

Basic information

• Product Name: 6-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol
• Synonyms: 6-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol;(3β,5Z,7E)-3-[[(1,1-DiMethylethyl)diMethylsilyl]oxy]-9,10-secocholesta-5,7,10(19)-triene-25-diol;3-O-TBDMS 25;3-O-tert-ButyldiMethylsilyl Calcifediol;3-O-tert-ButyldiMethylsilyl-25-Hydroxycholecalciferol;3-O-tert-ButyldiMethylsilyl-25-hydroxyvitaMin D3
• CAS NO: 140710-90-3
• Molecular Formula: C₃₃H₅₈O₂Si
• Molecular Weight: 0
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 140710-90-3.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Refractive Index: 1.508
• CAS DataBase Reference: 6-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 6-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol(140710-90-3)
• EPA Substance Registry System: 6-(4-{2-[5-(tert-Butyl-dimethyl-silanyloxy)-2-methylene-cyclohexylidene]-ethylidene}-7a-methyl-octahydro-inden-1-yl)-2-methyl-heptan-2-ol(140710-90-3)

Safety Data

• Hazardous Substances Data: 140710-90-3(Hazardous Substances Data)

Usage

Uses

A protected Calcifediol (C125700), a hydroxylated metabolite of Vitamin D3.

InChI:InChI=1/C33H58O2Si/c1-24-15-18-28(35-36(9,10)31(3,4)5)23-27(24)17-16-26-14-12-22-33(8)29(19-20-30(26)33)25(2)13-11-21-32(6,7)34/h16-17,25,28-30,34H,1,11-15,18-23H2,2-10H3/b26-16+,27-17+/t25-,28+,29-,30?,33-/m1/s1

Upstream product

• 19356-17-3 25-hydroxycholecalciferol 
• 73809-11-7 (S)-3-[(R)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidenemethyl]-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ⁶-benzo[c]thiophen-5-ol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 19356-17-3 (S)-3-[2-[(1R,3aS)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-4-methylene-cyclohexanol 
• 170081-45-5 3(S)-<(tert-butyldimethylsilyl)oxy>-20(S)-(iodomethyl)-9,10-secopregna-5(E),7(E),10(19)-triene 
• 917-64-6 methyl magnesium iodide 
• 140710-91-4 (R)-6-{(1R,3aS,7aR)-4-[1-[(S)-6-(tert-Butyl-dimethyl-silanyloxy)-2,2-dioxo-2,3,4,5,6,7-hexahydro-1H-2λ⁶-benzo[c]thiophen-1-yl]-meth-(E)-ylidene]-7a-methyl-octahydro-inden-1-yl}-2-methyl-heptan-2-ol 
• 19356-17-3 calcidiol 
• 1190696-99-1 des-A,B-25-(ethoxymethyloxy)cholestan-8-one 
• 100858-27-3 (S)-(Z)-{2-[5-(tert-butyldimethylsiloxy)-2-methylenecyclohexylidene]ethyl}diphenylphosphine oxide 

Downstream Products

• 1307302-42-6 1α,25-di-tetrahydropyranyloxy-3β-tert-butyldimethysilyl-5Z-vitamin D3 
• 1307302-43-7 1α,25-di-tetrahydropyranyloxy-5Z-vitamin D3 
• 1307302-44-8 C₃₉H₆₁BrO₆ 
• 132054-64-9 1α-[((trimethylsilyl)-oxy)]-3β-[((tertiary-butyl-dimethylsilyl)-oxy)], 25-trihydroxy-9,10-5(Z),7(E),10(19)-triene 
• 132054-64-9 1α,25-dihydroxy-5E-vitamin D3-3β-tert-butyldimethylsilyl ether 
• 1233749-00-2 3β,25-dihydroxy-9,10-secocholesta-5(E),7(E),10(19)-triene 
• 132054-64-9 (1S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-[2-[(1R,3aS)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(Z)-ylidene]-2-methylene-cyclohexanol 
• 32222-06-3 1α,25-dihydroxycholecalciferol 
• 132054-64-9 (1S,5R)-5-(tert-Butyl-dimethyl-silanyloxy)-3-[2-[(1R,3aS)-1-((R)-5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-(4E)-ylidene]-eth-(E)-ylidene]-2-methylene-cyclohexanol 

Relevant articles and documents

Preparation of ORMOSIL nanoparticles conjugated with vitamin D3 analogues and their biological evaluation

Dye-doped, 90 nm diameter, multifunctional organically modified silica (ORMOSIL) nanoparticles were prepared by condensation of vinyltriethoxysilane within surfactant-stabilized microemulsions and conjugated with several vitamin D3 derivatives. For this, vitamin D analogues possessing at least one hydroxyl group derivatized as vinylcarbonate have been synthesized. These analogues were conjugated to ORMOSIL nanoparticles through the carbonate function, forming carbamate derivatives of vitamin D nanoparticles. The interaction between these nanoparticles and human serum albumin, which is one of the serum transporters of the insoluble vitamin D3, was investigated by surface plasmon resonance. The results obtained revealed that this approach allows obtaining water-soluble vitamin D3 derivatives, which maintain their full protein binding ability.

1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: Synthesis and molecular mechanism of action

Synthesis of 1α,25-dihydroxyvitamin D3-3β- bromoacetate (1,25(OH)2D3-3-BE), a potential anti-cancer agent is presented. We also report that mechanism of action of 1,25(OH) 2D3-3-BE may involve reducti